Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
3SBio (HK:1530)
:1530
1530 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$4.91 - HK$7.85
Previous CloseN/A
Volume7.16M
Average Volume (3M)11.18M
Market Cap
$15.64B
Enterprise ValueHK$16.47B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)8.8
Beta0.89
Next Earnings
Mar 19, 2025EPS Estimate
0.38Last Dividend Ex-Date
Jul 22, 2024Dividend Yield3.75%
Share Statistics
EPS (TTM)0.74
Shares Outstanding2,395,574,000
10 Day Avg. Volume16,586,820
30 Day Avg. Volume11,175,607
Standard Deviation0.13
R-Squared0.23
Alpha0.00136
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.80
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
3SBio News
PremiumCompany Announcements
3SBio Partners with Duality Biologics for HER2 ADC Drug Commercialization
PremiumCompany Announcements
3SBio Cancels Treasury Shares and Relocates OfficePremiumCompany Announcements
3SBio Partners with Sunshine Lake Pharma for Drug Rights
PremiumCompany Announcements
3SBio’s Mandi Shines in 2024 Double 11 Sales
PremiumCompany Announcements
3SBio CFO Boosts Shareholding, Confident in Future
PremiumCompany Announcements
3SBio Secures Exclusive Rights for Cancer DrugPremiumCompany Announcements
3SBio Issues Supplemental Share Grant InfoPremiumCompany Announcements
3SBio Awards Shares to Top Performers---
Bulls Say, Bears Say
Bulls Say
Product PerformanceTPIAO's sales showed impressive growth, rising 22.6% year-over-year, contributing significantly to 3SBio's total revenue.
Revenue Growth3SBio reported a 16% year-over-year increase in revenue, aligning with forecasts and demonstrating strong financial performance.
Bears Say
Pricing PressureEPO sales may face ongoing pressure with a potential 40% price cut in Zhejiang under the volume-based procurement policy.
Profit MarginAttributable net profit margin declined by 1.1 percentage points due to increased R&D expenses and higher effective income tax rates.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
3.83% Mutual Funds
― Other Institutional Investors
93.05% Public Companies and
Individual Investors
1530 FAQ
What was 3SBio’s price range in the past 12 months?
3SBio lowest stock price was HK$4.91 and its highest was HK$7.85 in the past 12 months.
What is 3SBio’s market cap?
3SBio’s market cap is $15.64B.
When is 3SBio’s upcoming earnings report date?
3SBio’s upcoming earnings report date is Mar 19, 2025 which is in 24 days.
How were 3SBio’s earnings last quarter?
3SBio released its earnings results on Aug 22, 2024. The company reported HK$0.482 earnings per share for the quarter, beating the consensus estimate of HK$0.471 by HK$0.011.
Is 3SBio overvalued?
According to Wall Street analysts 3SBio’s price is currently Overvalued.
Does 3SBio pay dividends?
3SBio pays a Annually dividend of HK$0.25 which represents an annual dividend yield of 3.75%. See more information on 3SBio dividends here
What is 3SBio’s EPS estimate?
3SBio’s EPS estimate is 0.38.
How many shares outstanding does 3SBio have?
3SBio has 2,395,574,000 shares outstanding.
What happened to 3SBio’s price movement after its last earnings report?
3SBio reported an EPS of HK$0.482 in its last earnings report, beating expectations of HK$0.471. Following the earnings report the stock price went down -0.466%.
Which hedge fund is a major shareholder of 3SBio?
Currently, no hedge funds are holding shares in HK:1530
---
3SBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.62%
12-Months-Change
Fundamentals
Return on Equity
11.96%
Trailing 12-Months
Asset Growth
3.32%
Trailing 12-Months
Company Description
3SBio
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products. It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. The company was founded by Jing Lou and Dan Lou in 1993 and is headquartered in Shenyang, China.
---
1530 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
CSPC Pharmaceutical Group
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Best Analysts Covering 1530
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+10.70%
reiterated a buy rating 6 months ago
Copying Jill Wu's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +10.70% per trade.
---